De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Vitrolife Beheer

Beheer criteriumcontroles 2/4

De CEO Vitrolife's is Bronwyn Brophy O´Connor, benoemd in Aug2023, heeft een ambtstermijn van 1.17 jaar. De totale jaarlijkse vergoeding van { bedraagt SEK 7.44M, bestaande uit 74.5% salaris en 25.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.014% van de aandelen van het bedrijf, ter waarde SEK 4.86M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.2 jaar en 6.8 jaar.

Belangrijke informatie

Bronwyn Brophy O´Connor

Algemeen directeur

SEK 7.4m

Totale compensatie

Percentage CEO-salaris	74.5%
Dienstverband CEO	1.2yrs
Eigendom CEO	0.01%
Management gemiddelde ambtstermijn	1.2yrs
Gemiddelde ambtstermijn bestuur	6.8yrs

Recente managementupdates

Recent updates

Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)

Aug 21

Vitrolife AB (publ) Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next

Jul 20

Vitrolife AB (publ) (STO:VITR) Shares Fly 32% But Investors Aren't Buying For Growth

Jul 18

Vitrolife (STO:VITR) Is Carrying A Fair Bit Of Debt

Apr 03

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Mar 07

Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now

Feb 05

An Intrinsic Calculation For Vitrolife AB (publ) (STO:VITR) Suggests It's 27% Undervalued

Aug 25

Vitrolife (STO:VITR) Could Easily Take On More Debt

Aug 03

Are Vitrolife AB (publ) (STO:VITR) Investors Paying Above The Intrinsic Value?

May 26

Is Vitrolife (STO:VITR) A Risky Investment?

Jan 23

Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly

Oct 18

Calculating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Sep 09

Is Vitrolife (STO:VITR) A Risky Investment?

Jul 07

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

May 26

Vitrolife (STO:VITR) Seems To Use Debt Rather Sparingly

Mar 31

Estimating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Feb 07

There May Be Reason For Hope In Vitrolife's (STO:VITR) Disappointing Earnings

Apr 29

Analyse CEO-vergoeding

Hoe is Bronwyn Brophy O´Connor's beloning veranderd ten opzichte van Vitrolife's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-SEK 4b
Mar 31 2024	n/a	n/a	-SEK 4b
Dec 31 2023	SEK 7m	SEK 6m	-SEK 4b

Compensatie versus markt: De totale vergoeding ($USD 717.44K ) Bronwyn } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Swedish markt ($USD 1.03M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Bronwyn te vergelijken met de prestaties van het bedrijf.

CEO

Bronwyn Brophy O´Connor (50 yo)

1.2yrs

Tenure

SEK 7,439,000

Compensatie

Ms. Bronwyn Brophy O´Connor is President and Chief Executive Officer at Vitrolife AB (publ) since joining from August 01, 2023. She has an impressive track record as a leader of global Life science and Med...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Bronwyn Brophy O´Connor	CEO & President	1.2yrs	SEK 7.44m	0.014% SEK 4.5m
Patrik Tolf	Chief Financial Officer	2.8yrs	geen gegevens	0.0096% SEK 3.0m
Claus Bisgaard	Senior Vice President of Technologies	no data	geen gegevens	0.00028% SEK 88.9k
Guillermo Ferrando	Vice President Strategy & Corporate development	1.8yrs	geen gegevens	geen gegevens
Olivia Natens	Senior Vice President of Sales & Marketing	less than a year	geen gegevens	geen gegevens
Frank Pettersson	Acting Senior Vice President of HR & Sustainability	less than a year	geen gegevens	0.0013% SEK 416.1k
Rickard Ericsson	Senior Vice President of Consumables	less than a year	geen gegevens	0.0061% SEK 1.9m
Ricardo Capella	Senior Vice President Genetic Services	2.8yrs	geen gegevens	0.0044% SEK 1.4m

1.2yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VITR wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Henrik Blomquist	Director	5.4yrs	SEK 883.00k	0.0081% SEK 2.6m
Jon Sigurdsson	Chairman of the Board	9.8yrs	SEK 16.30m	0.022% SEK 7.1m
Lars Holmqvist	Independent Director	6.8yrs	SEK 450.00k	geen gegevens
Pia Marions	Independent Director	11.5yrs	SEK 500.00k	0.0037% SEK 1.2m
Karen Soerensen	Independent Director	4.3yrs	SEK 500.00k	geen gegevens

6.8yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VITR wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).

Vitrolife Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Vitrolife AB (Publ) Announces Election Committee Appointments

Director recently bought kr1.6m worth of stock

Vitrolife AB (publ) Announces Election Committee Appointments

Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice President

Insufficient new directors

Vitrolife AB Announces Board Changes

Recent updates

Vitrolife AB (Publ) Announces Election Committee Appointments

Now 20% overvalued after recent price rise

Now 20% overvalued after recent price rise

Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)

Vitrolife AB (publ) to Report Q3, 2025 Results on Oct 29, 2025

Price target increased by 7.2% to kr248

Vitrolife AB (publ) Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Vitrolife AB (publ) (STO:VITR) Shares Fly 32% But Investors Aren't Buying For Growth

Vitrolife AB (publ) (OM:VITR) acquired Stb Zorg B.V.

Director recently bought kr1.6m worth of stock

Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million.

Vitrolife AB (Publ) Approves Dividend for the Financial Year 2023

Upcoming dividend of kr1.00 per share

First quarter 2024 earnings released: EPS: kr0.85 (vs kr0.74 in 1Q 2023)

Now 22% undervalued

Dividend increased to kr1.00

Vitrolife (STO:VITR) Is Carrying A Fair Bit Of Debt

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now

Full year 2023 earnings: EPS misses analyst expectations

Vitrolife AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023

Vitrolife AB (publ)'s (STO:VITR) Share Price Matching Investor Opinion

Here's Why We Think Vitrolife (STO:VITR) Is Well Worth Watching

Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)

Is Vitrolife (STO:VITR) A Risky Investment?

Investor sentiment improves as stock rises 21%

Price target decreased by 8.9% to kr257

Third quarter 2023 earnings released: EPS: kr0.90 (vs kr0.80 in 3Q 2022)

Vitrolife AB (publ) Announces Election Committee Appointments

An Intrinsic Calculation For Vitrolife AB (publ) (STO:VITR) Suggests It's 27% Undervalued

Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice President

Insufficient new directors

Vitrolife (STO:VITR) Could Easily Take On More Debt

Vitrolife AB Announces Board Changes

Chief Financial Officer recently bought kr335k worth of stock

Consensus EPS estimates fall by 16%

Price target decreased by 7.4% to kr292

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 15%

Vitrolife AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

Are Vitrolife AB (publ) (STO:VITR) Investors Paying Above The Intrinsic Value?

Chief Financial Officer recently bought kr535k worth of stock

Chief Financial Officer recently bought kr535k worth of stock

Upcoming dividend of kr0.85 per share at 0.4% yield

Full year 2022 earnings: EPS misses analyst expectations

Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021)

Vitrolife AB (publ) Proposes Dividend for 2022

Vitrolife AB (publ) Announces Executive Changes

Is Vitrolife (STO:VITR) A Risky Investment?

Price target decreased to kr260

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Vitrolife AB (publ) to Report First Half, 2023 Results on Jul 14, 2023

Investor sentiment improved over the past week

Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly

Vitrolife AB (publ) Announces Election Committee Appointments

Price target decreased to kr307

Now 30% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Vitrolife AB (Publ) Announces Retirement of Thomas Axelsson as CEO

Calculating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Vitrolife AB (publ), Annual General Meeting, Apr 27, 2023

Is Vitrolife (STO:VITR) A Risky Investment?

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Chief Financial Officer recently bought kr496k worth of stock

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations